Episode Details
Back to Episodes
PharmAla Biotech Creates U.S. MDMA Hub, De-Risking Clinical Trials | PharmAla Biotech (CSE:MDMA) | The Watchlist E3
Description
In this episode of The Watchlist, we're joined by Nicholas Kadyshr, CEO of PharmAla Biotech (CSE:MDMA). He discusses the company's major strategic moves: establishing a U.S. distribution hub for its LaNeo MDMA and launching PharmAla Australia as a dedicated R&D center for its next-generation molecule, ALA-02.
Listeners will hear Nicholas Kadyshr discuss:
The strategic importance of establishing an R&D hub in Australia for the ALA-02 molecule.
How a U.S. distribution depot for LaNeo MDMA removes import/export friction for key clinical trial partners.
The unique business model of combining drug manufacturing with drug discovery and development in the controlled substance space.
How these strategic moves in the U.S. and Australia position the company for long-term leadership.
For more information, visit: https://www.pharmalabiotech.com/
This podcast is made in partnership with PharmAla Biotech. The views expressed in this podcast are not investment advice. Investing in securities is speculative and involves a high degree of risk. For our full disclaimer, visit: https://themarketonline.ca/disclaimer
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.